162 related articles for article (PubMed ID: 11102429)
1. In vitro activity of gemifloxacin and five other fluoroquinolones against defined isogenic mutants of Escherichia coli, Pseudomonas aeruginosa and Staphylococcus aureus.
Schulte A; Heisig P
J Antimicrob Chemother; 2000 Dec; 46(6):1037-8. PubMed ID: 11102429
[No Abstract] [Full Text] [Related]
2. Studies to establish quality control ranges for SB-265805 (LB2030) when using National Committee for Laboratory Standards antimicrobial susceptibility test methods. Quality Control Study Group.
Erwin ME; Jones RN
J Clin Microbiol; 1999 Jan; 37(1):279-80. PubMed ID: 9988595
[No Abstract] [Full Text] [Related]
3. Staphylococcus aureus and Escherichia coli adhesion to human cells is reduced by sub-MICs of gemifloxacin.
Braga PC; Dal SM; Woodnutt G
J Chemother; 2002 Feb; 14(1):41-6. PubMed ID: 11892898
[TBL] [Abstract][Full Text] [Related]
4. The bactericidal activity of gemifloxacin (SB-265805).
Morrissey I; Clark S; Mathias I
J Med Microbiol; 2000 Sep; 49(9):841-844. PubMed ID: 10966234
[TBL] [Abstract][Full Text] [Related]
5. Gemifloxacin and ciprofloxacin pharmacodynamics in an in-vitro dynamic model: prediction of the equivalent AUC/MIC breakpoints and doses.
Firsov AA; Zinner SH; Lubenko IYu ; Vostrov SN
Int J Antimicrob Agents; 2000 Dec; 16(4):407-14. PubMed ID: 11118849
[TBL] [Abstract][Full Text] [Related]
6. Comparison of agar dilution, microdilution, Etest and disc diffusion to test the activity of trovafloxacin against Pseudomonas aeruginosa, methicillin-resistant Staphylococcus aureus and Streptococcus pneumoniae.
Kelly LM; Jacobs MR; Appelbaum PC
J Antimicrob Chemother; 1999 May; 43(5):707-9. PubMed ID: 10382894
[TBL] [Abstract][Full Text] [Related]
7. Comparative anti-staphylococcal effects of gemifloxacin and trovafloxacin in an in vitro dynamic model in terms of AUC/MIC and dose relationships.
Zinner SH; Vostrov SN; Lubenko IY; Portnoy YA; Cornaglia G; Firsov AA
Diagn Microbiol Infect Dis; 2001 Aug; 40(4):167-71. PubMed ID: 11576789
[TBL] [Abstract][Full Text] [Related]
8. Urine bactericidal activity after administration of gemifloxacin and trovafloxacin single doses in a phase I study.
García-Calvo G; Parra A; Ponte C; Soriano F; Giménez MJ; Aguilar L
Int J Antimicrob Agents; 2002 Dec; 20(6):477-80. PubMed ID: 12458147
[No Abstract] [Full Text] [Related]
9. Topoisomerase targeting with and resistance to gemifloxacin in Staphylococcus aureus.
Ince D; Zhang X; Silver LC; Hooper DC
Antimicrob Agents Chemother; 2003 Jan; 47(1):274-82. PubMed ID: 12499202
[TBL] [Abstract][Full Text] [Related]
10. Phenotypic resistance of Staphylococcus aureus, selected Enterobacteriaceae, and Pseudomonas aeruginosa after single and multiple in vitro exposures to ciprofloxacin, levofloxacin, and trovafloxacin.
Gilbert DN; Kohlhepp SJ; Slama KA; Grunkemeier G; Lewis G; Dworkin RJ; Slaughter SE; Leggett JE
Antimicrob Agents Chemother; 2001 Mar; 45(3):883-92. PubMed ID: 11181375
[TBL] [Abstract][Full Text] [Related]
11. Bactericidal activity of trovafloxacin (CP-99,219).
Morrissey I
J Antimicrob Chemother; 1996 Dec; 38(6):1061-6. PubMed ID: 9023654
[TBL] [Abstract][Full Text] [Related]
12. [In vitro short-term bactericidal activity and accumulation of NM394, the active metabolite of prulifloxacin, for Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa: comparison with ciprofloxacin, levofloxacin, and gatifloxacin].
Shimizu M; Tabata M; Hara T; Araake M; Watabe H; Nishino T
Jpn J Antibiot; 2002 Dec; 55(6):791-9. PubMed ID: 12621733
[TBL] [Abstract][Full Text] [Related]
13. Antibacterial properties of gemifloxacin and trovafloxacin in urine ex vivo: phase I study.
García-Calvo G; Parra A; Aguilar L; Ponte C; Giménez MJ; Carcas A; Kinzig-Schippers M; Soriano F
Antimicrob Agents Chemother; 2001 Jun; 45(6):1876-8. PubMed ID: 11353641
[TBL] [Abstract][Full Text] [Related]
14. Accumulation and killing kinetics of fifteen quinolones for Escherichia coli, Staphylococcus aureus and Pseudomonas aeruginosa.
Asuquo AE; Piddock LJ
J Antimicrob Chemother; 1993 Jun; 31(6):865-80. PubMed ID: 8360125
[TBL] [Abstract][Full Text] [Related]
15. The in-vitro activity and tentative breakpoint of gemifloxacin, a new fluoroquinolone.
Wise R; Andrews JM
J Antimicrob Chemother; 1999 Nov; 44(5):679-88. PubMed ID: 10552986
[TBL] [Abstract][Full Text] [Related]
16. In vitro activity of gemifloxacin against a broad range of recent clinical isolates from the USA.
McCloskey L; Moore T; Niconovich N; Donald B; Broskey J; Jakielaszek C; Rittenhouse S; Coleman K
J Antimicrob Chemother; 2000 Apr; 45 Suppl 1():13-21. PubMed ID: 10824027
[TBL] [Abstract][Full Text] [Related]
17. In vitro susceptibility of Neisseria meningitidis isolates to gemifloxacin and ten other antimicrobial agents.
Vázquez JA; Berrón S; Giménez MJ; de la Fuente L; Aguilar L
Eur J Clin Microbiol Infect Dis; 2001 Feb; 20(2):150-1. PubMed ID: 11305475
[No Abstract] [Full Text] [Related]
18. Postantibiotic effect of trovafloxacin against gram-positive and -negative organisms.
Pankuch GA; Jacobs MR; Appelbaum PC
Antimicrob Agents Chemother; 1998 Jun; 42(6):1503-5. PubMed ID: 9624503
[TBL] [Abstract][Full Text] [Related]
19. Postantibiotic effects of E-4868 and OPC-17116.
Sanford MD; Jones RN
J Antimicrob Chemother; 1993 Dec; 32(6):916-7. PubMed ID: 8144440
[No Abstract] [Full Text] [Related]
20. Intracellular penetration and activity of gemifloxacin in human polymorphonuclear leukocytes.
García I; Pascual A; Ballesta S; Joyanes P; Perea EJ
Antimicrob Agents Chemother; 2000 Nov; 44(11):3193-5. PubMed ID: 11036051
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
